Corrigendum: Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [Ann Oncol, 26 (Suppl 5), (2015) (v56-v68)]doi 10.1093/annonc/mdv295;Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 26, Issue , 2015, Pages v56-v68

  Ducreux, M ^a,b   Cuhna, A Sa ^b,c   Caramella, C ^a   Hollebecque, A ^a   Burtin, P ^a   Goere D ^a   Seufferlein, T ^d   Haustermans, K ^e   Van Laethem, J L ^f   Conroy, T ^g   Arnold, D ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e Leuven Kankerinstitute ^*  (Belgium)

^f ERASME HOSPITAL   (Belgium)

^g Institut de Cancérologie de Lorraine Alexis Vautrin   (France)

^h TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

AGE; ARTICLE; BILIARY TRACT DRAINAGE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CARCINOGENESIS; CHEMORADIOTHERAPY; DRUG EFFICACY; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY;

COMBINED MODALITY THERAPY; HUMANS; PANCREAS; PANCREATIC NEOPLASMS;

EID: 84941646402     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx258     Document Type: Erratum

References (58)

1. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2014. Ann Oncol 2014; 25: 1650-1656.
2. Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol 2015; 42: 8-18.
3. Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 2012; 106: 603-607.
4. Ojajarvi IA, Partanen TJ, Ahlbom A et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 2000; 57: 316-324.
5. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 2015; 44: 186-198.
6. Rishi A, Goggins M, Wood LD, Hruban RH. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol 2015; 42: 28-39.
7. Wisnoski NC, Townsend CM, Jr, Nealon WH et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery 2008; 144: 141-148.
8. Dudeja V, Allen PJ. Premalignant cystic neoplasms of the pancreas. Semin Oncol 2015; 42: 70-85.
9. Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. World J Gastroenterol 2014; 20: 13833-13841.
10. Waddell N, Pajic M, Patch AM et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.
11. Nawaz H, Fan CY, Kloke J et al. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP 2013; 14: 484-497.
12. Al-Hawary MM, Francis IR, Chari ST et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 2014; 270: 248-260.
13. Bipat S, Phoa SS, van Delden OM et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005; 29: 438-445.
14. Callery MP, Chang KJ, Fishman EK et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
15. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol 2008; 6: 1301-1308.
16. Ngamruengphong S, Swanson KM, Shah ND, Wallace MB. Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer. Gut 2015; 64: 1105-1110.
17. Abrams RA, Lowy AM, O'Reilly EM et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16: 1751-1756.
18. Bockhorn M, Uzunoglu FG, Adham M et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014; 155: 977-988.
19. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2015 Pancreatic Adenocarcinoma. http://www.nccn.org.
20. Delpero JR, Bachellier P, Regenet N et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford) 2014; 16: 20-33.
21. Delpero JR, Boher JM, Sauvanet A et al. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the association francaise de chirurgie. Ann Surg Oncol 2015; 22: 1874-1883.
22. Mitchem JB, Hamilton N, Gao F et al. Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg 2012; 214: 46-52.
23. Kooby DA, Hawkins WG, Schmidt CM et al. A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg 2010; 210: 779-785.
24. Ricci C, Casadei R, Taffurelli G et al. Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: a systematic review and metaanalysis. J Gastrointest Surg 2015; 19: 770-781.
25. Tol JA, Gouma DJ, Bassi C et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014; 156: 591-600.
26. Ragulin-Coyne E, Carroll JE, Smith JK et al. Perioperative mortality after pancreatectomy: a risk score to aid decision-making. Surgery 2012; 152(3 Suppl. 1): S120-S127.
27. van der Gaag NA, Rauws EA, van Eijck CH et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137.
28. Neoptolemos JP, Dunn JA, Stocken DD et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585.
29. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
30. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081.
31. Marechal R, Bachet JB, Mackey JR et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143: 664-674.
32. Assifi MM, Lu X, Eibl G et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011; 150: 466-473.
33. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267.
34. Denost Q, Laurent C, Adam JP et al. Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head. HPB (Oxford) 2013; 15: 716-723.
35. Landry J, Catalano PJ, Staley C et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 2010; 101: 587-592.
36. Hammel P, Huguet F, Van Laethem J-L et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 2013;31(suppl): abstr LBA4003.
37. Shinchi H, Takao S, Noma H et al. Length and quality of survival after externalbeam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002; 53: 146-150.
38. Sultana A, Tudur Smith C, Cunningham D et al. Systematic review, including metaanalyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96: 1183-1190.
39. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced nonmetastatic pancreatic cancer: a FFCD-SFRO study. J Clin Oncol 2006; 24(suppl): abstr 4008.
40. Loehrer PJ, Sr, Feng Y, Cardenes H et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105-4112.
41. Mukherjee S, Hurt CN, Bridgewater J et al. Gemcitabine-based or capecitabinebased chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14: 317-326.
42. Stark A, Hines OJ. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. Semin Oncol 2015; 42: 163-176.
43. Ripamonti CI, Santini D, Maranzano E et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23(Suppl 7): vii139-vii154.
44. Burris HA, III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
45. Ciliberto D, Botta C, Correale P et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013; 49: 593-603.
46. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
47. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
48. Von Hoff DD, Goldstein D, Renschler MF. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med 2014; 370: 479-480.
49. Oettle H, Riess H, Stieler JM et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423-2429.
50. Sonnenblick A, Kadouri L, Appelbaum L et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 2011; 12: 165-168.
51. Chmielecki J, Hutchinson KE, Frampton GM et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov 2014; 4: 1398-1405.
52. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
53. Blackford A, Serrano OK, Wolfgang CL et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15: 4674-4679.
54. Klumpen HJ, Queiroz KC, Spek CA et al. mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome. J Clin Oncol 2011; 29: e150-e153.
55. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009; 361: 2094-2096.
56. Greenhalf W, Ghaneh P, Neoptolemos JP et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014; 106: djt347.
57. Ormanns S, Siveke JT, Heinemann V et al. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer 2014; 14: 624.
58. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.